International travel to and immigration from tropical countries have increased over the past decades. As expected, diseases are imported from tropical areas and are regularly seen at health services in industrialized countries.This fact has been recognized for malaria, and efforts have been directed toward sensitizing the public and physicians to the danger of this disease. 1, 2 Much less attention has been focused on individuals with other imported parasitic infections.Although helminthic diseases cause less morbidity and mortality than does malaria, strongyloidosis, in particular, can cause serious health problems. Patients with altered cell-mediated immunity are at risk for dissemination and hyperinfection, particularly those receiving corticosteroids or having human T-lymphotropic virus 1 infection, and, to a lesser extent, those with acquired immunodeficiency syndrome. [3] [4] [5] [6] [7] Hyperinfection with dissemination of larvae, leakage of gut flora from a bowel damaged by moving larvae, and enteric bacteria carried by invasive larvae can result in bloodstream infection, meningitis, and pneumonia with a high mortality rate. 8 The mortality rate among patients hospitalized for strongyloidosis has been estimated to be up to 16.7%. 9 Around 30 to 100 million people are estimated to be infected with Strongyloides stercoralis in endemic areas of South America, South and Southeast Asia, sub-Saharan Africa, and the Appalachian region of the United States. 10 In Europe pockets of low endemicity have been described. [11] [12] [13] In Switzerland the disease occurs only sporadically, and the last published report dates from 1975. 14 The absence of endemic strongyloidosis allows the medical community to focus on imported cases. Among imported helminthic diseases, strongyloidosis has probably the highest impact on health. 9 Our analysis of patients with imported strongyloidosis aims to bring about a better assessment of its clinical characteristics, diagnosis, and management.
Patients and Methods

Patients
The Swiss Tropical Institute is the referral center for tropical diseases and offers primary and tertiary outpatient care for tropical diseases and travel medicine.The Medical Outpatient Department of Internal Medicine of the University Hospital of Basel offers primary and Background: Attention regarding imported tropical diseases is typically focused on malaria, although other parasitic diseases such as strongyloidosis may also cause serious health problems. The importance of assessing clinical features and of proper diagnosis and treatment is presented on the basis of 31 patients with imported strongyloidosis.
Methods: A retrospective analysis was performed regarding patients treated for strongyloidosis in two referral centers in Switzerland from 1998 to 2002.
Results: Imported strongyloidosis was investigated in 12 travelers and 19 immigrants. The reasons for diagnostic workup were clinical symptoms in 84% and eosinophilia and screening in each of 22.5%. All patients had a history of travel or residence in endemic areas. Initial therapy was effective in 20 patients, and there was a tendency for a better response to ivermectin compared with the response to other drugs. A significant reduction in blood eosinophil count and serologic antibody titer was observed in patients responding to therapy after an average of 96 and 270 days, respectively.
Conclusions: Strongyloidosis must be suspected in travelers and immigrants with skin or abdominal symptoms from regions where Strongyloides stercoralis is highly endemic. The results of this case series confirm that ivermectin is the drug of choice in treating imported strongyloidosis. Response to therapy can be assessed by serology and differential white blood count performed over 6 months after therapy.
tertiary care to the population of the city of Basel and is a managed care organization for asylum seekers in Basel. Larvae of S. stercoralis were discerned using the Baermann technique: stool is put on a mesh screen and a coarse tissue that is filled with distilled water, and connected to a tubing.After 2 hours of incubation under light, larvae crawl out of the fecal mass and migrate into the water, warmed by the light bulb.This fluid is then centrifuged, and the larvae are detected in the sediment. 15 Serologic diagnosis was done using an enzyme-linked immunosorbent assay (ELISA) for detecting immunoglobulin G (IgG) (heavy plus light chains) against crude extract of the third-stage larvae of Strongyloides ratti. 16 Patients treated for strongyloidosis at these institutions qualified for the study. Regimens used for the treatment of strongyloidosis were ivermectin 200 µg/kg qd on 2 consecutive days, albendazole 12 to 15 mg/kg qd for 10 days, and thiabendazole 25 mg/kg bid for 10 days.
Data Collection
Patients treated for strongyloidosis from 1998 to 2002 were identified by screening the databases of the Swiss Tropical Institute and the University Hospital of Basel using the World Health Organization International Classification of Diseases and Related Health Problems, versions 9 and 10. Codes of discharge diagnosis for strongyloidosis were used.Charts of candidates generated by the database search were screened for confirmed strongyloidosis. A resident and an attending physician performed a chart review of these patients using a data extraction form.
Data Analysis
All data were stored in a computerized database.The data were analyzed independently by two physicians. Quantitative parameters are given as means (Ϯ SD) when normally distributed. Otherwise, they are presented as medians (minimum Ϫ maximum). Qualitative parameters are given as proportions (percentage). Differences were calculated by means of a Fisher exact test on a 2 ϫ 2 table for proportions and Wilcoxon signed rank test or t-test for quantitative data. Statistical analysis was performed with the software Stat View 5.0 (SAS Institute).
Results
The database search yielded 58 potentially relevant cases of strongyloidosis. Twenty-five of them had been treated for parasitic diseases other than strongyloidosis. Records of 2 patients (3.4%) were missing. Data on 31 patients were available for the analysis. Patient characteristics are shown in Table 1 . Using the Baermann technique, strongyloidosis was diagnosed by detection of larvae in stool samples in 20 patients (65%).In the remaining 11 patients (35%), the disease was diagnosed on clinical suspicion, corroborated by positive serology and concomitant blood eosinophilia.The disease was acquired by traveling in endemic areas in 12 patients (39%).They were infected while walking barefoot in exposed areas during travel in South America (n = 5),Africa (n = 4), India (n = 1),and the Middle East (n = 1) and through unknown exposure in one case. Reason for travel were leisure (n = 6), business (n = 3), study (n = 1), mission (n = 1), and unknown (n = 1). Nineteen patients (61%) were immigrants, the majority of which came from South and Southeast Asia (n = 8),Africa (n = 6), and South America (n = 5). Diagnostic work-up was triggered by clinical symptoms in most cases,followed by blood eosinophilia and untargeted broad helminthic serologic screening. The most common symptoms were cramping abdominal pain (n = 12), diarrhea (n = 6), dry coughing (n = 6), and urticarial or erythematous rash (n = 6).The pathognomonic feature of larva currens was described in only one patient. Fever (n = 4), arthralgia (n = 1), and weight loss (n = 1) occurred rarely. Sixteen percent of the patients were asymptomatic. Overall symptoms occurred in 84% of the immigrants and in 83% of the travelers. However, abdominal symptoms were less frequent in immigrants (47% vs 75%).This was also true for skin problems (16% vs 25%). Pulmonary symptoms were more frequent in immigrants (25% vs 8.3%). These differences did not reach statistical significance. Serology was positive in 19 of 19 (100%) immigrants and 9 of 12 (75%) travelers.
Response to anthelmintic therapy was defined as the disappearance of parasites in three stool samples performed at least 6 weeks after therapy. If larvae had not been detected initially, the disappearance of symptoms and of blood eosinophilia was considered a cure.The initial therapy was effective in 20 (65%) patients; 11 patients experienced a relapse. Characteristics of patients who responded to their first anthelmintic therapy in comparison with those who experienced relapse are shown in Table 2 . Compared with other treatments (albendazole, n = 14; thiabendazole, n = 1), relapses occurred less frequently among the 15 patients treated with ivermectin (3/16 vs 7/15, p = .09).A significant reduction in eosinophil counts measured after 96 (Ϯ 124) days was observed in responders (p < .05). Antibody titers of follow-up serology decreased significantly in the responder group after an average of 270 (Ϯ 305) days (p < .05).
Discussion
More than one-third of the 31 patients with S. stercoralis infection were recorded among travelers. The remaining patients were immigrants from endemic countries. The most frequent factor leading to a diagnostic work-up was unspecific symptoms, mostly of the gastrointestinal tract. Response to therapy was characterized by the disappearance of larvae from the stools and/or a significant reduction of antibody titers and eosinophil counts. Patients tended to respond better to ivermectin than to albendazole and thiabendazole.Various studies investigating the prevalence of S. stercoralis in high endemic areas have shown prevalence rates around 2 to 20%. [17] [18] [19] As expected, many of the imported cases were seen among immigrants.Another important factor was travel to endemic regions. An investigation of strongyloidosis in US veterans of the Vietnam War showed prevalence rates of 1.6% in asymptomatic patients and of 5% in symptomatic patients. 20 An infrequently seen but characteristic sign of strongyloidosis is larva currens, a transient, highly pruritic dermatitis caused by the short-term intradermal migration of the filariform larvae in the skin.This sign has been N u e s ch e t a l , I m p o rt e d S t r o n g y l o i d o s i s most frequently found in white patients who acquired strongyloidosis in Southeast Asia.When specifically investigated,the symptom has been found in up to 92% of corresponding patients. [21] [22] [23] However,in most cases,including our study, symptoms of chronic strongyloidosis tend to be intermittent and not specific: abdominal pain (~55%), anorexia (~25%), diarrhea (~45%), cough (~35%), and urticaria (~65%). [21] [22] [23] Such data suggest that strongyloidosis should be suspected and searched for in patients with a possible exposure to penetrating third-stage larvae through the skin, especially if unspecific gastrointestinal and pulmonary symptoms or rash are present.
The fact that almost one-quarter of the strongyloidosis in patients in this series was detected by untargeted screening among travelers and immigrants points out the respective risk of missing the diagnosis. However, the optimal diagnostic strategy is still a matter of debate. 24 Definitive diagnosis of strongyloidosis is usually made by the detection of larvae in the stool.The sensitivity of this procedure is disappointingly low. 21 In some studies, the diagnostic sensitivity was increased to 50% with three stool samples and rose to 100% if seven serial stool samples were examined. 21, 25 Also, the chance of finding the larvae depends on the detection method. In various detection techniques including direct fecal smear, formalin-ethyl concentration, Harada-Mori filter paper culture, Baermann concentration, and agar plate culture, the agar plate culture method was found to have the best sensitivity. 26, 27 In a study among expatriates returning from the tropics, eosinophilia > 450 cells/µL had a sensitivity of 38% and a specificity 90% for the detection of invasive parasitic diseases. 28 ELISA tests for detecting serum IgG against antigens of S. stercoralis have shown sensitivities around 90% and specificities of 29 to 99%, depending on how cross-reaction with filarial and echinococcal antigens were assessed. 29, 30 In our study stool samples were positive in 20 patients (65%).Twenty-three of 31 patients (74%) had an eosinophil count > 450 cells/µL, and 28 (90%) had a positive serology. Cross-reactive serology to filarial (71%) and echinococcal antigens (57%) was common. 16 Interestingly, and as also reported in a recently published study, serology was positive in 100% of immigrants but only in 75% of travelers. 31 In agreement with this study, we also found fewer abdominal symptoms among immigrants than among travelers.
Serology and white blood cell count were useful to assess response to therapy.This was characterized by a significant decrease in eosinophilia and antibody titers. Although the antibody titers also decreased in patients who did not respond to the initial therapy (probably owing to a reduction of antigen load), this decrease was not significant. The decrease in serologic titers and eosinophil counts as a marker of treatment success is confirmed by the findings of a recent study. 32 Twenty patients (65%) responded to the initial drug regimen, and there was a tendency to a better response in patients treated with ivermectin. This confirms the results of prospective studies in endemic areas. [33] [34] [35] [36] In a randomized controlled trial, ivermectin was compared with thiabendazole. There were no significant differences in the cure rate but a much lower prevalence of side effects. 35 Thiabendazole is no longer available in Switzerland and many other countries. Other randomized controlled trials have compared ivermectin with albendazole. They showed significantly better cure rates with ivermectin (83%) than with albendazole (38-43%). 34, 36 A limitation of our study is its retrospective design; it would be interesting to prospectively evaluate response to therapy by serology and eosinophil count in a standardized way. Nevertheless, the quality of the data is improved by the facts that data abstraction was performed by two physicians independently and that treatment outcome was documented in all patients.
Conclusions
Strongyloidosis must be suspected in symptomatic travelers and immigrants to and from regions where S. stercoralis is highly endemic. In these patients diagnostic work-up should include peripheral white blood cell count and serology. In the case of blood eosinophilia or positive serology, detection of larvae with a concentration technique in three stool samples should be performed. Ivermectin at a dosage of 200 µg/kg qd on 2 consecutive days appears to be the most effective drug regimen. Response to therapy can be assessed by serology and blood count performed more than 6 months after therapy.
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